Search results
Author(s):
Philipp Lurz
Added:
9 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation…
View more
Author(s):
Philipp Lurz
,
Jorg Hausleiter
,
Maria Körber
,
et al
Added:
2 years ago
In this programme, a leading faculty delve into the groundbreaking advancements in the treatment of severe tricuspid regurgitation with the innovative EdwardsEVOQUE Tricuspid Valve Replacement System. This session features an informative "Live in a Box" transcatheter tricuspid replacement valve case by Prof Jörg Hausleiter. It provides a comprehensive analysis of the patient selection criteria,…
View more
Author(s):
Harriette Van Spall
,
Helene Eltchaninoff
Added:
1 year ago
ESC Congress 2024 — Transcatheter aortic valve replacement shows superiority over surgical aortic valve replacement for women with severe aortic stenosis.Host, Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Helene Eltchaninoff (University Hospital of Rouen, FR) to discuss key findings from the RHEIA trial (NCT04160130; Optimapharm).This prospective, randomised study aims to…
View more
Author(s):
Bandar Alshehri
,
Hussein Alamri
,
Naif Alghasab
,
et al
Added:
1 year ago
Author(s):
Felipe Eduardo Macías Prado
,
Jhon Mario German Gaibor
,
Rafel Ernesto Portaluppi Cervantes
,
et al
Added:
6 months ago
Author(s):
Susheel Kodali
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a…
View more
Peter Sever
Author
Author(s):
Brian Lindman
Added:
1 year ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Author(s):
Ole De Backer
Added:
2 years ago
EuroPCR 24 - We are joined onsite by Prof Ole De Backer (Rigshospitalet, DK) to discuss the findings from the NOTION-2 Study. (NCT02825134).NOTION-2 is a randomized, multicenter trial which aimed to investigate transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in 376 patients under 75 years of age with severe aortic valve stenosis in regard to intra-…
View more
Author(s):
Marc Dweck
Added:
1 year ago
TCT Conference 2024 - Clinical outcomes of early intervention in patients with asymptomatic aortic stenosis (AS) did not impact the composite primary outcome of all cause mortality and unplanned AS related hospitalisation.Dr Marc Dweck (University of Edinburgh, Edinburgh, UK) joins us in this short interview filmed onsite at TCT Conference to discuss the findings from EVOLVED (NCT03094143;…
View more